Why the study?
Does Alda-1 reduce infarct size in rat models of cardiac ischemia?
Does Alda-1 reduce infarct size in rat models of cardiac ischemia?
Pharmacologic activation of ALDH2 with Alda-1 reduces ischemic cardiac damage in rodent models, suggesting a potential therapeutic strategy for myocardial infarction or cardiac surgery.
Answers are grounded in this paper and cite their sources.
Supports ALDH2 activation for cardioprotection in rodents; hypothesis-generating and should not yet change clinical practice.
There is substantial interest in the development of drugs that limit the extent of ischemia-induced cardiac damage caused by myocardial infarction or by certain surgical procedures. Here, using an unbiased proteomic search, we identified mitochondrial aldehyde dehydrogenase 2 (ALDH2) as an enzyme whose activation correlates with reduced ischemic heart damage in rodent models. A high-throughput screen yielded a small-molecule activator of ALDH2 (Alda-1) that, when administered to rats before an ischemic event, reduced infarct size by 60%, most likely through its inhibitory effect on the formation of cytotoxic aldehydes. In vitro, Alda-1 was a particularly effective activator of ALDH2*2, an inactive mutant form of the enzyme that is found in 40% of East Asian populations. Thus, pharmacologic enhancement of ALDH2 activity may be useful for patients with wild-type or mutant ALDH2 who are subjected to cardiac ischemia, such as during coronary bypass surgery.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: